Back to Search Start Over

Gastrointestinal peptides and small-bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn's disease.

Authors :
Khalaf A
Hoad CL
Menys A
Nowak A
Radford S
Taylor SA
Latief K
Lingaya M
Falcone Y
Singh G
Spiller RC
Gowland PA
Marciani L
Moran GW
Source :
The American journal of clinical nutrition [Am J Clin Nutr] 2020 Jan 01; Vol. 111 (1), pp. 131-140.
Publication Year :
2020

Abstract

Background: Crohn's disease (CD) patients suffer postprandial aversive symptoms, which can lead to anorexia and malnutrition. Changes in the regulation of gut hormones and gut dysmotility are believed to play a role.<br />Objectives: This study aimed to investigate small-bowel motility and gut peptide responses to a standard test meal in CD by using MRI.<br />Methods: We studied 15 CD patients with active disease (age 36 ± 3 y; BMI 26 ± 1 kg/m 2) and 20 healthy volunteers (HVs; age 31 ± 3 years; BMI 24 ± 1 kg/m 2). They underwent baseline and postprandial MRI scans, symptom questionnaires, and blood sampling following a 400-g soup meal (204 kcal). Small-bowel motility, other MRI parameters, and glucagon-like peptide-1 (GLP-1), polypeptide YY (PYY), and cholecystokinin peptides were measured. Data are presented as means ± SEMs.<br />Results: HVs had significantly higher fasting motility indexes [106 ± 13 arbitrary units (a.u.)], compared with CD participants (70 ± 8 a.u.; P ≤ 0.05). Postprandial small-bowel water content showed a significant time by group interaction (P < 0.05), with CD participants showing higher levels from 210 min postprandially. Fasting concentrations of GLP-1 and PYY were significantly greater in CD participants, compared with HVs [GLP-1, CD 50 ± 8 µg/mL versus HV 13 ± 3 µg/mL (P ≤ 0.0001); PYY, CD 236 ± 16 pg/mL versus HV 118 ± 12 pg/mL (P ≤ 0.0001)]. The meal challenge induced a significant postprandial increase in aversive symptom scores (fullness, distention, bloating, abdominal pain, and sickness) in CD participants compared with HVs (P ≤ 0.05).<br />Conclusions: The decrease in fasting small-bowel motility noted in CD participants can be ascribed to the increased fasting gut peptides. A better understanding of the etiology of aversive symptoms in CD will facilitate identification of better therapeutic targets to improve nutritional status. This trial was registered at clinicaltrials.gov as NCT03052465.<br /> (Copyright © American Society for Nutrition 2019. All rights reserved.)

Details

Language :
English
ISSN :
1938-3207
Volume :
111
Issue :
1
Database :
MEDLINE
Journal :
The American journal of clinical nutrition
Publication Type :
Academic Journal
Accession number :
31557279
Full Text :
https://doi.org/10.1093/ajcn/nqz240